Low-Dose Naltrexone (LDN)

LDN appears relatively safe and well tolerated at the doses studied. The most common side effects are mild and transient: insomnia, vivid dreams, nausea, and dizziness — generally resolving within the first few weeks. Serious adverse events are rare in LDN studies. However, safety data comes primarily from short-term studies (weeks to months), not long-term use (years). The safety profile of LDN does NOT mean it is effective — it means it is unlikely to cause harm at the doses studied.

Individual patient reports of improvement on LDN are common in online communities. Several factors may explain this: spontaneous improvement (conditions like fibromyalgia naturally fluctuate), placebo effect (which is real and measurable — belief in a treatment can produce genuine symptom relief), and the possibility that a subset of patients genuinely respond to LDN through mechanisms not yet understood. The 2026 review suggests N-of-1 trials — where individual patients alternate between LDN and placebo while tracking symptoms — as a way to identify genuine responders.

Yes, but it is an off-label prescription. Doctors can legally prescribe naltrexone for off-label indications at their clinical discretion. The practical challenge is obtaining the low dose: naltrexone is manufactured only as 50 mg tablets. A compounding pharmacy must prepare the low-dose capsules. Alternatively, some patients are instructed to dissolve a 50 mg tablet in 50 mL of water and take a measured volume with an oral syringe — but this approach carries dosing accuracy risks and should only be done under explicit medical guidance.

It is the same medication (naltrexone hydrochloride) at a much lower dose. The key differences: addiction treatment uses 50 mg daily (oral) or 380 mg monthly (injection); LDN uses 0.5–6.0 mg daily. The mechanisms are thought to be different — addiction treatment relies on continuous opioid receptor blockade, while LDN theory involves transient blockade followed by rebound endorphin production and possible immune modulation. Because of this dose difference, you cannot use standard 50 mg naltrexone tablets for LDN without accurate dose reduction (compounding or supervised dilution).

At LDN doses (0.5–6.0 mg), the interaction with opioids is less pronounced than at the standard 50 mg dose, but it still exists. LDN can partially block opioid effects and theoretically trigger withdrawal in opioid-dependent patients. If you take opioid pain medications, discuss this with your doctor before considering LDN. Some LDN protocols require a washout period before starting. Conversely, if you are on LDN and require emergency pain relief, inform healthcare providers — they may need to use non-opioid alternatives or higher opioid doses.

Ask: (1) Is there clearer evidence that this will help my specific condition? (2) What other treatments with stronger evidence have we not tried? (3) If we try LDN, how will we objectively measure whether it is working? (4) How long should we trial it before deciding it is ineffective? (5) Can we structure this as an N-of-1 trial — alternating LDN and placebo while I track symptoms? (6) What compounding pharmacy do you recommend, and how do I verify the dose accuracy?